Johnson & Johnson, Takeda, Novartis and Bukwang Pharmaceutical all backed the first round disclosed by oncology drug developer Immpact Bio USA.
US-based cellular cancer therapy developer Immpact Bio USA completed an $18m funding round on Tuesday featuring pharmaceutical firms Johnson & Johnson, Takeda, Novartis and Bukwang Pharmaceutical.
The round included RM Global Partners BioPharma, OrbiMed, Hayan Health Networks and JVC Investment Partners, with Takeda, Johnson & Johnson and Novartis investing through Takeda Ventures, Johnson & Johnson Innovation – JJDC and Novartis Venture Fund respectively.
Founded in 2017 as a project within biotech incubator FutuRx, Immpact Bio is working on therapeutics by…
